Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Alector reported a Phase 2 failure for an AbbVie-partnered Alzheimer’s program Monday afternoon and said it will need to lay off staff. Researchers were examining whether the drug, known as AL002, could slow the progression ...